| gap-pubmed-20260410- | What determines the competitive binding dynamics between PLCβ4 and PLCγ1 for PIP | open | 0.79 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How does cadmium exposure specifically upregulate PLCβ4 expression in male but n | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neurotoxicology |
| gap-pubmed-20260410- | What molecular mechanisms determine the male-specific vulnerability to cadmium-i | open | 0.80 | 0.00 | 2026-04-10 | 0 | | developmental-neurotoxicology |
| gap-pubmed-20260410- | What mechanisms coordinate tPA release from multiple cell types during cerebral | open | 0.69 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | How do NMDAR and LRP-1 receptors differentially mediate tPA's contradictory effe | open | 0.76 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | What determines when tPA's effects are plasmin-dependent versus plasmin-independ | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cerebrovascular |
| gap-pubmed-20260410- | Why does CB1R deletion cause severe pain specifically in females but not males? | open | 0.79 | 0.00 | 2026-04-10 | 0 | | pain-neurobiology |
| gap-pubmed-20260410- | How do mPFC CaMKIIα neurons specifically regulate vlPAG GABA neuron activity? | open | 0.83 | 0.00 | 2026-04-10 | 0 | | pain-neurobiology |
| gap-pubmed-20260410- | What molecular mechanisms underlie sexually dimorphic CB1R expression on CaMKIIα | open | 0.80 | 0.00 | 2026-04-10 | 0 | | pain-neurobiology |
| gap-pubmed-20260410- | How do canonical and non-canonical TGFβ pathway modulations coordinate to drive | open | 0.75 | 0.00 | 2026-04-10 | 0 | | signal-transduction |
| gap-pubmed-20260410- | Why does enhanced neurogenesis through TGFβ inhibition specifically benefit ALS | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does TGFβ-RII antisense treatment enhance human neural progenitor differenti | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurogenesis |
| gap-pubmed-20260410- | Why is lysine 70 the specific ubiquitination site on PFN1, and do other lysine r | open | 0.74 | 0.00 | 2026-04-10 | 0 | | protein-biochemistry |
| gap-pubmed-20260410- | How does SP1-mediated FBXL4 repression initiate during cardiac hypertrophy and w | open | 0.77 | 0.00 | 2026-04-10 | 0 | | cardiac-pathophysiology |
| gap-pubmed-20260410- | How does TNFα neutralization prevent sleep deprivation-induced tau pathology and | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does CPSR but not TSD lead to tau hyperphosphorylation and amyloid-beta depo | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do bFGF and GDNF mechanistically suppress Aβ-induced TG2 overexpression in g | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive TG2 subcellular relocalization from nucleus to c | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do PALB2 and ATG7/autophagy pathways mechanistically cooperate to maintain n | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why are Purkinje cells specifically vulnerable to PALB2 deletion compared to oth | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link PALB2 to mitochondrial homeostasis beyond its est | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What drives the upregulation of B4GALT6 and LacCer synthesis during chronic CNS | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does LacCer regulate differential production of CCL2 versus GM-CSF in astroc | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms mediate LacCer's autocrine control of astrocyte transc | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does metabolic reprogramming of glucose and lipids regulate microglial phago | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which exercise modulates microglia | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the broader role of P2X7 receptors in neurodegenerative processes beyond | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does P2X7 receptor activation by ATP lead to cytotoxicity in neurodegenerati | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific factors that regulate IL-1 expression, cleavage and releas | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines the temporal sequence from peripheral metabolic dysregulation to | open | 0.73 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How can mechanistic findings from preclinical models be effectively translated t | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific molecular mechanisms drive the crosstalk between obesity-induced p | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does lipoamide stabilize intrinsically disordered proteins while simultaneou | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the precise molecular mechanism linking SFPQ redox state changes to stre | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does lipoamide's redox modulation specifically target stress granule protein | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does sulforaphane selectively reduce HDAC2 levels without affecting other HD | open | 0.76 | 0.00 | 2026-04-10 | 0 | | epigenetics |
| gap-pubmed-20260410- | Does sulforaphane's neuroprotective effect require continuous HDAC inhibition or | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which specific BDNF promoters are targeted by sulforaphane-induced histone acety | open | 0.80 | 0.00 | 2026-04-10 | 0 | | epigenetics |
| gap-pubmed-20260410- | Why does IL-6 elevation persist for at least one month after acute stress in sus | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does peripheral IL-6 communicate with the brain to influence stress-related | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms link preexisting peripheral IL-6 sensitivity to subseq | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do the identified protein-metabolite interactions translate to actionable dr | open | 0.70 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does LILRB1 show protective effects against AD while other identified protei | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which protein-metabolite pairs med | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the laterality differences in ALPS index recovery patterns acros | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does gBOLD-CSF coupling recover while structural glymphatic markers remain p | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive the nonlinear fluctuation pattern of white matter free wat | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines whether shared genetic variants manifest as cardiovascular disea | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do C1Q-mediated inflammatory pathways differ between heart macrophages and b | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which PLEC upregulation contribute | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |